Business Strategy

CEL-SCI's vision is to change the way cancer is treated. We strive to develop novel immune-based therapies with potential to utilize the body's own immune defense system against disease with the possibility of minimal toxicity to normal cells and organ systems>
In theory small companies such as ours should not ever be successful. But in practice and reality small companies are the engines of change. We are one of those small engines of change. We have shown very meaningful long term (5-year) survival benefits for patients in a very large Phase 3 head and neck cancer study. Join us and help us change the world for the better.

CEL-SCI's lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is currently being developed as a potential therapeutic agent directed at enabling the immune system to use the body's own anti-tumor immune response.

Read more...

History

CEL-SCI’s story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, many times lack of funding, a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer and having to switch the Clinical Research Organization that initially ran the Phase 3 trial, CEL-SCI is finally approaching the end game!